Earnings History Data for Finch Therapeutics Group, Inc. (FNCH) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Finch Therapeutics Group, Inc.

Finch Therapeutics Group Inc. is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery(R) platform to develop a novel class of orally administered biological drugs. The company's product candidate includes CP101, FIN-211, FIN-524 and FIN-525. Finch Therapeutics Group Inc. is based in SOMERVILLE, Mass.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
10-05-2023	PM		FNCH	Finch Therapeutics Group	19.00	-0.52	-0.09	0.00	Finch Therapeutics GAAP EPS of -$1.33 misses by $1.24, revenue of $0.11M [5/10/2023 1:37 PM]	0.4119	-0.01 (-1.93%)	0.40	-0.02 (-4.29%)	0.30 - 3.00	46,913	160,000	201
Finch Therapeutics GAAP EPS of -$1.33 misses by $1.24, revenue of $0.11M [5/10/2023 1:37 PM]
23-03-2023	AH		FNCH	Finch Therapeutics Group	21.00	-0.56	-0.39	0.00	Finch Therapeutics GAAP EPS of -$0.56 [3/23/2023 4:43 PM]	0.35	-0.05 (-12.50%)	0.0	0.0 (0.00%)	0.30 - 5.79	88,723	120,000	0
Finch Therapeutics GAAP EPS of -$0.56 [3/23/2023 4:43 PM]
10-11-2022	PM	7:00 AM ET (Nov 10)	FNCH	Finch Therapeutics Group, Inc.	60.09	-0.45	-0.40	-0.21	Finch Therapeutics GAAP EPS of -$0.85 misses by $0.45 [11/10/2022 9:20 AM]	1.07	0.05 (4.39%)	1.00	-0.03 (-2.44%)	1.01 - 17.39	50,458	50,000	217
Finch Therapeutics GAAP EPS of -$0.85 misses by $0.45 [11/10/2022 9:20 AM] Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference [Nov-09-22 08:00AM] Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results [Nov-10-22 07:00AM]
11-08-2022	PM		FNCH	Finch Therapeutics Group	117.00	-0.48	-0.46	0.00	Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M [8/11/2022 9:09 AM]	2.63	0.03 (1.15%)	2.60	0.0 (0.00%)	1.71 - 17.39	47,302	50,000	1,587
Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M [8/11/2022 9:09 AM] Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results [Aug-11-22 07:00AM] Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation [Aug-10-22 08:06AM]
16-05-2022	PM		FNCH	Finch Therapeutics Group, Inc.	96.54	-0.52	0.00	1.00	Finch Therapeutics GAAP EPS of -$0.52, revenue of $0.35M [5/16/2022 9:39 AM]	2.12	-0.11 (-4.93%)	2.31	0.08 (3.59%)	1.71 - 22.10	185,488	510,000	2,872
Finch Therapeutics GAAP EPS of -$0.52, revenue of $0.35M [5/16/2022 9:39 AM] Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results [May-16-22 07:00AM]
31-03-2022	AH	After the close (Mar 31)	FNCH	Finch Therapeutics Group, Inc.	244.52	-0.40	-0.42	0.00	Finch Therapeutics GAAP EPS of -$0.40, revenue of $0.8M [3/31/2022 5:22 PM]	4.78	-0.25 (-4.97%)	5.02	0.0 (0.00%)	4.52 - 22.10	57,058	40,000	203
Finch Therapeutics GAAP EPS of -$0.40, revenue of $0.8M [3/31/2022 5:22 PM] Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates [Mar-31-22 04:56PM]
10-11-2021	PM		FNCH	Finch Therapeutics Group, Inc.	663.81	-0.21	-0.42	0.00	Finch Therapeutics EPS beats by $0.07 [11/10/2021 9:05 AM]	14.44	-0.34 (-2.30%)	15.51	0.73 (4.94%)	11.56 - 22.50	83,359	100,000	2,425
Finch Therapeutics EPS beats by $0.07 [11/10/2021 9:06 AM] Finch Therapeutics EPS beats by $0.07 [11/10/2021 9:05 AM] Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection [Nov-09-21 04:30PM] Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates [Nov-10-21 07:05AM] Finch Therapeutics Announces Transition of Chief Medical Officer [Nov-10-21 07:00AM] Finch Therapeutics' C. Difficile Infection Candidate Meets Primary Goal In Mid-Stage Study [Nov-10-21 07:15AM]
10-08-2021	PM		FNCH	Finch Therapeutics Group, Inc.	654.00	-0.32	-0.28	0.00	Finch Therapeutics EPS misses by $0.04 [8/10/2021 7:38 AM]	14.00	0.21 (1.52%)	0.0	0.0 (0.00%)	11.56 - 22.50	24,404	20,000	0
Finch Therapeutics EPS misses by $0.04 [8/10/2021 7:38 AM] Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update [Aug-10-21 07:05AM] Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program [Aug-10-21 07:00AM] Takeda To Lead Finch-Partnered Microbiome IBD Drug [Aug-10-21 03:54PM]